Recruiting
Investigational
A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis
Investigational
- Substances:–
Countries:
Spain
Spain- Participants:18–64 years
Find therapies in clinical trials near you
- recruiting
- 3 962
- countries
- 28
- conditions
- 2 101
3 962 trials recruiting28 European countries2 101 conditions coveredUpdated today
13 trials match your criteria
Recruiting
Primary progressive multiple sclerosis
RecruitingInvestigational
Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis
Investigational
- Disease:Primary progressive multiple sclerosis
- Substances:–
Countries:Spain
Spain- Participants:18–64 years
Recruiting
Multiple sclerosis
RecruitingRegistered drug
A study of RO7268489 added to ocrelizumab compared to placebo in adults with progressive multiple sclerosis
Registered drug
- Disease:Multiple sclerosis
- Substances:OcrelizumabRO7268489
Countries:Spain
Spain- Participants:18–64 years
- Substances:Ocrelizumab
Recruiting
Relapsing multiple sclerosis
RecruitingRegistered drugNo placebo
Study comparing remibrutinib and ocrelizumab in patients with relapsing multiple sclerosis who switch from ocrelizumab treatment
Registered drugNo placebo
- Disease:Relapsing multiple sclerosis
- Substances:OcrelizumabRemibrutinib
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Ocrelizumab
Not yet recruiting
Relapsing-remitting multiple sclerosis
Not yet recruitingRegistered drugNo placebo
Study Comparing ABP 692 and Ocrelizumab for Patients with Relapsing-Remitting Multiple Sclerosis
Registered drugNo placebo
- Disease:Relapsing-remitting multiple sclerosis
- Substances:Ocrelizumab
Countries:Spain
Spain- Participants:18–64 years
- Substances:Ocrelizumab
Not recruiting
Dermatitis acneiform
Not recruitingInvestigational
A study testing aprepitant gel for treating skin rash in cancer patients receiving epidermal growth factor receptor inhibitor therapy
Investigational
- Disease:Dermatitis acneiform
- Substances:Aprepitant
Countries:Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Aprepitant
Not recruiting
Primary progressive multiple sclerosis
Not recruitingInvestigational
Study on Tolebrutinib for Patients with Primary Progressive Multiple Sclerosis
Investigational
- Disease:Primary progressive multiple sclerosis
- Substances:Tolebrutinib
Countries:Spain
Spain- Participants:18–64 years
- Substances:Tolebrutinib
Not recruiting
Multiple sclerosis relapse
Not recruitingRegistered drugNo placebo
Study on Long-Term Safety and Effectiveness of Ofatumumab for Patients with Relapsing Multiple Sclerosis
Registered drugNo placebo
- Disease:Multiple sclerosis relapse
- Substances:OfatumumabA/Darwin/6/2021(H3N2)-Like Strain (A/Darwin/11/2021, Wild Type)+42
Countries:Spain
Spain- Participants:18–64 years
- Substances:Ofatumumab
Not recruiting
Relapsing multiple sclerosis
Not recruitingRegistered drug
Study on the Effectiveness and Safety of Remibrutinib Compared to Teriflunomide for Patients with Relapsing Multiple Sclerosis
Registered drug
- Disease:Relapsing multiple sclerosis
- Substances:Charcoal, ActivatedColestyramine+3
Countries:Spain
Spain- Participants:18–64 years
- Substances:Charcoal, Activated
Not recruiting
Multiple sclerosis relapse
Not recruitingRegistered drugNo placebo
Study on the Effectiveness and Tolerability of Ofatumumab Compared to a Drug Combination for Patients with Newly Diagnosed Relapsing Multiple Sclerosis
Registered drugNo placebo
- Disease:Multiple sclerosis relapse
- Substances:Dimethyl FumarateDiroximel Fumarate+6
Countries:Spain
Spain- Participants:18–64 years
- Substances:Dimethyl Fumarate
Not recruiting
Multiple sclerosis
Not recruitingRegistered drugNo placebo
Study on Long-Term Safety and Efficacy of Ocrelizumab for Patients with Multiple Sclerosis
Registered drugNo placebo
- Disease:Multiple sclerosis
- Substances:Ocrelizumab
Countries:Spain
Spain- Participants:18–64 years
- Substances:Ocrelizumab
Not recruiting
Morning sickness
Not recruitingRegistered drugNo placebo
Study on Doxylamine and Pyridoxine for Pregnant Women with Nausea and Vomiting
Registered drugNo placebo
- Disease:Morning sickness
- Substances:Doxylamine Hydrogen SuccinatePyridoxine Hydrochloride
Countries:Spain
Spain- Participants:18–64 years
- Substances:Doxylamine Hydrogen Succinate